NL-OMON46979已完成3 期
Comparing the effectiveness and costs of bevacizumab to ranibizumab in patients with retinal vein occlusions - BRVO
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 228
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* Male or female patients > 18 years of age with recent vision loss due to foveal center-involved ME secondary to branch or central retinal vein occlusion who, in the opinion of the investigator, could have functional benefit from injections with a VEGF antagonist, and who have signed an informed consent.
- •* BCVA > 24 and < 78 letters in the study eye and, inclusively, using ETDRS- like visual acuity testing charts at a testing distance of 4 meters (approximate Snellen equivalent of 20/32 to 20/320) at screening.
- •* Mean central subfield thickness > 275 µm from 2 OCT measurements
排除标准
- •see also protocol 4.4
研究者
相似试验
已完成
3 期
Comparing the effectiveness and costs of bevacizumab to ranibizumab in patients with diabetic macular edemadiabetic macular edema10047060NL-OMON47349Academisch Medisch Centrum126
已完成
不适用
Comparison of bevacizumab (Avastin) and ranibizumab (Lucentis) in exudative age-related macular degeneration.eyeretinaangiogenesisbevacizumabranibizumaboogleeftijdsgebonden maculadegeneratieage-related macular degenerationLucentisAvastinchoroidal neovascularizationNL-OMON21233Prof. Dr. R.O. SchlingemannDepartment of Ophthalmology, Room A2-122Academisch Medisch CentrumMeibergdreef 91105 AZ AmsterdamTel +31205663616e-mail: r.schlingemann@amc.uva.nl306
尚未招募
不适用
BRVO.macular edema secondary to a retinal vein occlusionNL-OMON23545Academic Medical Center (AMC)Department of Ophthalmology296
Unknown
2 期
Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO)Retinal Vein OcclusionNCT01635803Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)296
Unknown
2 期
Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Diabetic Macular Edema (BRDME)Diabetic Macular EdemaNCT01635790Prof. dr. R.O. Schlingemann246